Erlotinib is an orally administered anticancer agent that un…
Erlotinib is an orally administered anticancer agent that undergoes elimination via both renal and hepatic pathways. The drug exhibits an oral bioavailability of approximately 60%. Following oral administration, if 20% of the administered dose is recovered unchanged in feces, determine the hepatic extraction ratio (ER) for this drug. Assume that the liver is the sole site of metabolic clearance and that biliary excretion of the unchanged drug is negligible.